Ocular Therapeutix
OCUL
71 hedge funds and large institutions have $197M invested in Ocular Therapeutix in 2015 Q4 according to their latest regulatory filings, with 16 funds opening new positions, 24 increasing their positions, 20 reducing their positions, and 15 closing their positions.
608% more call options, than puts
Call options by funds: $262K | Put options by funds: $37K
20% more repeat investments, than reductions
Existing positions increased: 24 | Existing positions reduced: 20
1% more funds holding
Funds holding: 70 → 71 (+1)
7% more first-time investments, than exits
New positions opened: 16 | Existing positions closed: 15
25% less funds holding in top 10
Funds holding in top 10: 4 → 3 (-1)
36% less capital invested
Capital invested by funds: $309M → $197M (-$112M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$7.75M |
| 2 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$3.25M |
| 3 |
Millennium Management
New York
|
+$2.99M |
| 4 |
ARTA
A.R.T. Advisors
New York
|
+$1.04M |
| 5 |
CCI
Columbus Circle Investors
|
+$397K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LCP
Lamond Capital Partners
San Francisco,
California
|
-$17.3M |
| 2 |
FCM
Farallon Capital Management
San Francisco,
California
|
-$3.81M |
| 3 |
PCM
Portolan Capital Management
Boston,
Massachusetts
|
-$3.68M |
| 4 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
-$1.59M |
| 5 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
-$1.58M |
OCUL Hedge Fund Activity: Q4 2015 in Review
71 of the 3,824 institutional investors tracked by Wall St. Rank reported a position in Ocular Therapeutix (OCUL) for Q4 2015, worth a combined $197M — down 36% from $309M a quarter earlier.
Buyers outnumbered sellers: 16 funds opened new OCUL positions and 15 closed out — a net gain of 1 holder — while 24 added to existing stakes and 20 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $7.75M. The largest seller was Lamond Capital Partners, exiting entirely with an estimated $17.3M sold.
- 71 institutional investors held Ocular Therapeutix (OCUL) as of Q4 2015, up from 70 in Q3 2015.
- Funds reported $197M of Ocular Therapeutix stock for Q4 2015, down 36% quarter-over-quarter.
- 16 funds opened new Ocular Therapeutix positions in Q4 2015 and 15 closed out, a net change of +1 holder.
- The largest Ocular Therapeutix buyer in Q4 2015 was Fidelity Investments, an estimated $7.75M added.
- The largest Ocular Therapeutix seller in Q4 2015 was Lamond Capital Partners, an estimated $17.3M sold.
Based on aggregated 13F filings for Q4 2015.